ASND - Ascendis Pharma A/S

QQQ $ 598.50 $ -5.24 (-0.87 %)

DIA $ 458.71 $ -3.77 (-0.81 %)

SPY $ 659.26 $ -6.23 (-0.93 %)

TLT $ 91.34 $ 0.85 (0.94 %)

GLD $ 396.80 $ 5.21 (1.33 %)

Previous Close

$ 207.12

Open

$ 207.12

Bid

$ 206.39 x 5

Ask

$ 215.23 x 5

Day's Range

$ 207.03 - $ 211.28

52 Week Range

$ 118.03 - $ 216.45

Volume

416,875

Average Volume

Market Cap

12.57B

Beta (5Y Monthly)

$ 0.74

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Maintains Overweight on ...
10/13/2025 13:37:25

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target fr...

JP Morgan Maintains Overweight on Ascendis...
10/09/2025 12:50:01

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $26...

Ascendis Pharma Submits Marketing Authoris...
10/08/2025 20:03:36

COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has submitted a Mar...

What Does the Market Think About Ascendis ...
09/29/2025 17:00:52

Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According t...

$100 Invested In Ascendis Pharma 10 Years ...
09/25/2025 23:00:33

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an...

PTC Therapeutics Could Challenge BioMarin ...
09/08/2025 17:56:24

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in...

$100 Invested In Ascendis Pharma 10 Years ...
09/08/2025 14:15:19

Here's How Much $100 Invested In Ascendis ...
09/04/2025 20:30:39

Ascendis To Present Latest Achondroplasia ...
09/02/2025 20:02:54

B of A Securities Maintains Buy on Ascendi...
09/02/2025 15:41:07

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $...

How Do Investors Really Feel About Ascendi...
08/28/2025 17:00:46

If You Invested $1000 In This Stock 10 Yea...
08/19/2025 15:00:31

JP Morgan Maintains Overweight on Ascendis...
08/19/2025 14:17:08

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $25...

Citigroup Maintains Buy on Ascendis Pharma...
08/08/2025 22:47:08

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $243 to...

RBC Capital Maintains Outperform on Ascend...
08/08/2025 17:22:18

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $21...

Wedbush Maintains Outperform on Ascendis P...
08/08/2025 16:07:45

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $212 to...

UBS Maintains Buy on Ascendis Pharma, Rais...
08/08/2025 15:54:26

UBS analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $306 to $307.

Cantor Fitzgerald Maintains Overweight on ...
08/08/2025 15:07:28

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target fr...

Stifel Maintains Buy on Ascendis Pharma, R...
08/08/2025 13:44:19

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $212 to $254.

Ascendis Pharma Q2 EPS US$(0.93) Beats US$...
08/07/2025 20:08:04

Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.4...